Osmundacetone Ameliorates Alzheimer's-like Pathologies by Inhibiting (3-Amyloid Fibrillation, Oxidative Damage and Neuroinflammation in APP/ PS1 Transgenic Mice

Ling-Xiao Zhao,Hang Ren,Jing-Yang Su,Qi Zhang,Da-Long He,Ting-Yao Wu,Yan-Hui Zhang,Zhan-You Wang,Yong-Gang Fan
DOI: https://doi.org/10.1016/j.phymed.2024.156091
IF: 6.656
2024-01-01
Phytomedicine
Abstract:Background: beta-Amyloid (A beta) fibrillation is critical for A beta deposition and cytotoxicity during the progression of Alzheimer's disease (AD). Consequently, anti-A beta monoclonal antibody drugs targeting A beta oligomers and aggregation are considered potential therapeutic strategies for AD treatment. Similar to the working mechanisms of anti-A beta monoclonal antibody drugs, our study identified osmundacetone (OAC), a small-molecule compound isolated from the traditional Chinese medicine Rhizoma Osmundae, as exerting anti-AD effects by targeting A beta. Purpose: This study sought to determine whether OAC influences the A beta burden in APP/PS1 mice and to identify potential regulatory mechanisms. Methods: Five-month-old APP/PS1 mice were injected intraperitoneally with OAC at a dose of 1 mg/kg for 12 weeks. The cognitive functions of the mice were assessed via the Morris water maze test and the open field test. Osmundacetone was analyzed via molecular docking, an isothermal dose-response fingerprint-cellular context thermal shift assay, a thioflavine T fluorescence assay, and an atomic force microscopy assay to analyze the effects of OAC on A beta fibrillation. Immunofluorescence, immunoblotting, and immunohistochemistry were used to assess A beta clearance, AD pathology, oxidative stress, and inflammatory responses. Results: The innovative biochemical and physical data illustrated that the ability of OAC to inhibit A beta fibrillation was accomplished by binding directly to A beta, which differed from the majority of previously reported natural polyphenols that modulate the A beta content and structure in an indirect manner. The inhibition of A beta fibrosis by OAC subsequently promoted A beta lysosomal degradation, resulting in a decreased A beta burden in APP/PS1 mice. Furthermore, OAC treatment inhibited oxidative damage by upregulating glutathione peroxidase expression and attenuated the production of inflammatory factors by downregulating nuclear factor-kB phosphorylation in APP/ PS1 mice. Conclusion: These findings demonstrate, for the first time, that OAC could reduce the brain A beta burden in APP/PS1 mice by inhibiting A beta fibrillation through direct binding to A beta and improve cognitive dysfunction by attenuating oxidative damage and neuroinflammation. These findings indicate that OAC may be a promising candidate for the treatment of AD.
What problem does this paper attempt to address?